Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
Y Tomita, T Ikeda, S Sakata, K Saruwatari, R Sato… - Cancer immunology …, 2020 - AACR
Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB).
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
Y Tomita, Y Goto, S Sakata, K Imamura… - …, 2022 - Taylor & Francis
Oral microbiota is associated with human diseases including cancer. Emerging evidence
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into …
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate into …
[HTML][HTML] Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI …
Y Sakata, S Sakata, Y Oya, M Tamiya, H Suzuki… - European Journal of …, 2021 - Elsevier
Background Osimertinib is the standard of care in the initial treatment for advanced epidermal
growth factor receptor (EGFR) mutation–positive lung cancer. However, clinical data and …
growth factor receptor (EGFR) mutation–positive lung cancer. However, clinical data and …
[HTML][HTML] Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer …
K Tanaka, K Nosaki, K Otsubo, K Azuma, S Sakata… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The T790M secondary mutation of the epidermal growth factor receptor (EGFR) gene
accounts for 50% to 60% of cases of resistance to the first-generation EGFR tyrosine kinase …
accounts for 50% to 60% of cases of resistance to the first-generation EGFR tyrosine kinase …
Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
S Sakata, K Otsubo, H Yoshida, K Ito… - Cancer …, 2022 - Wiley Online Library
Considering the increasing number of identified driver oncogene alterations, additional
genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (…
genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (…
[HTML][HTML] Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1/PD-L1 monoclonal antibodies
R Sato, K Imamura, S Sakata, T Ikeda, Y Horio… - Journal of clinical …, 2019 - mdpi.com
A disruption of immune checkpoints leads to imbalances in immune homeostasis, resulting
in immune-related adverse events. Recent case studies have suggested the association …
in immune-related adverse events. Recent case studies have suggested the association …
[HTML][HTML] Psb28 is involved in recovery of photosystem II at high temperature in Synechocystis sp. PCC 6803
S Sakata, N Mizusawa, H Kubota-Kawai… - … et Biophysica Acta (BBA …, 2013 - Elsevier
Psb28 is an extrinsic protein of photosystem II (PSII), which is conserved among
photosynthetic organisms from cyanobacteria to higher plants. A unicellular cyanobacterium, …
photosynthetic organisms from cyanobacteria to higher plants. A unicellular cyanobacterium, …
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer
…, CK Imamura, H Ogata, A Fujita, S Sakata… - Cancer …, 2017 - Wiley Online Library
Spliced variant isoforms of CD 44 ( CD 44v) are a marker of cancer stem cells in solid tumors.
They stabilize the xCT subunit of the transporter system xc(–) and thereby promote …
They stabilize the xCT subunit of the transporter system xc(–) and thereby promote …
Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell Lung Cancer: a real-world …
Y Sato, H Sumikawa, R Shibaki, T Morimoto, Y Sakata… - Chest, 2022 - Elsevier
Background Osimertinib has demonstrated impressive efficacy as a first-line treatment for
patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung …
patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung …
[HTML][HTML] Histologic transformation of epidermal growth factor receptor–mutated lung cancer
…, A Hata, H Suzuki, H Matsumoto, S Sakata… - European Journal of …, 2022 - Elsevier
Purpose This study aimed to determine the incidence and clinical course of epidermal growth
factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT). Patients …
factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT). Patients …